Medline Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Medline reported Q3 2026 net sales of $7.9B (+10.4% YoY) and nine-month sales of $22.9B (+10.9% YoY), with Adjusted EBITDA of $960M (+11.8%) and $2.8B (+5.0%) respectively. However, nine-month net income fell 28.8% to $696M, primarily due to a $316M net loss from a Tracy, California distribution center fire and tariff-related costs, partially offset by $324M in IEEPA tariff refunds. The company raised full-year organic sales guidance to 10.0%–10.5% (from 9.0%–10.0%), reaffirmed Adjusted EBITDA guidance of $3.3B–$3.4B, and the Board authorized a $1B share repurchase program; management also prepaid $750M of debt in October.
Why this rating
Strong organic sales growth and raised guidance are positive; major distribution fire loss and net income decline are negative. Net effect is moderate for a $13B company—$316M fire loss is ~2.4% of market cap, partially mitigated by tariff gains and solid cash generation ($1.8B FCF YTD).
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.